Title
Impact of early treatment of psoriasis on disease recurrence-Results from the STEPIn study
Type
research article
Institution
UNIL/CHUV/Unisanté + partner institutions
Author(s)
Iversen, Lars
Author
Langley, Richard G
Author
Gudjonsson, Johann E
Author
Eidsmo, Liv
Author
Narbutt, Joanna
Author
Czajkowski, Rafal
Author
Pinter, Andreas
Author
Pink, Andrew E
Author
Rivera-Diaz, Raquel
Author
Gianchandani, Dheeraj A
Author
Kolbinger, Frank
Author
Bao, Weibin
Author
Gaillez, Corine
Author
Jagiello, Piotr
Author
Conrad, Curdin
Author
Links to people
Links to units
ISSN
0190-9622
Editorial status
Published
Date Issued
2026-07
Volume
95
Issue
1
First page
95
Last page/article number
103
Peer-reviewed
True
Language
english
Abstract
Benefits of early intervention with secukinumab in patients with new-onset plaque psoriasis (disease duration: ≤1 year) were investigated in STEPIn study (NCT03020199).
To evaluate the proportion of patients maintaining sustained skin clearance in the treatment-free follow-up period up to week (W) 104 following withdrawal of secukinumab and narrow band ultraviolet B at W52.
Wald test was used for analysis of proportion of patients achieving PASI 90 (key secondary endpoint) from W52 through W104. Missing values were imputed using nonresponder imputation approach.
Overall, 93.5% (72/77) of patients completed 52 weeks in the secukinumab arm. At W104, 20.8% of patients who previously received secukinumab sustained PASI 90 responses. At W104, 11.7%, 22.1%, and 24.7% of patients previously treated with secukinumab sustained a PASI 100 response, IGA mod 2011 0/1 and PASI <3. Among secukinumab treated patients, 44% (29/66) who entered the treatment-free follow-up period at W52 did not relapse (loss of 50% of the maximum improvement in PASI following treatment cessation) until W104.
Absence of blinding due to open-label nature of the study.
Early intervention with secukinumab maintains efficacy in a subset of patients with new-onset moderate to severe psoriasis, 1-year following treatment withdrawal.
Copyright © 2026 The Author(s). Published by Elsevier Inc. All rights reserved.
To evaluate the proportion of patients maintaining sustained skin clearance in the treatment-free follow-up period up to week (W) 104 following withdrawal of secukinumab and narrow band ultraviolet B at W52.
Wald test was used for analysis of proportion of patients achieving PASI 90 (key secondary endpoint) from W52 through W104. Missing values were imputed using nonresponder imputation approach.
Overall, 93.5% (72/77) of patients completed 52 weeks in the secukinumab arm. At W104, 20.8% of patients who previously received secukinumab sustained PASI 90 responses. At W104, 11.7%, 22.1%, and 24.7% of patients previously treated with secukinumab sustained a PASI 100 response, IGA mod 2011 0/1 and PASI <3. Among secukinumab treated patients, 44% (29/66) who entered the treatment-free follow-up period at W52 did not relapse (loss of 50% of the maximum improvement in PASI following treatment cessation) until W104.
Absence of blinding due to open-label nature of the study.
Early intervention with secukinumab maintains efficacy in a subset of patients with new-onset moderate to severe psoriasis, 1-year following treatment withdrawal.
Copyright © 2026 The Author(s). Published by Elsevier Inc. All rights reserved.
PMID
Creation date in IRIS
2026-03-30T12:54:23Z